Novartis' ribociclib receives FDA Breakthrough status in breast cancer

3 August 2016

Swiss pharma giant Novartis (NOVN: VX) has received US Food and Drug Administration Breakthrough Therapy designation for LEE011 (ribociclib), in combination with letrozole, for hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.

LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor, and its designation is based primarily on positive results of the Phase III Monaleesa-2 trial which met the primary endpoint of clinically meaningful improvement in progression free survival (PFS) at a pre-planned interim analysis.

The trial assessed LEE011 in combination with letrozole in postmenopausal women who had received no prior therapy for their advanced disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK